For many people with a tear in the rubbery cartilage that cushions the knee, physical therapy may work just as well as surgery in terms of quieting pain and returning the joint’s function, a new study suggests.
Eli Lilly and Co.’s experimental diabetes treatment Ultra Rapid Lispro was shown to be as effective as the drugmaker’s blockbuster Humalog medicine in two late-stage studies.
Shares of Cambridge, Mass.-based Avrobio plunged more than 50 percent after the company provided an updated look at a gene therapy for Fabry disease that showed promise for the treatment, but also raised some concern for investors.
A single leukemia cell inadvertently got mixed in with a batch of a patient’s immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported.
Switzerland’s Roche is buying UK-based Tusk Therapeutics in a deal that could hit EUR 655 million.
Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.
A global coalition set up to fight emerging epidemics will give $19 million to drugmaker Johnson & Johnson’s vaccine unit and Oxford University experts to work on immunizations against three major diseases.
An experimental GlaxoSmithKline vaccine could prevent tuberculosis developing in half of those who receive it, making the vaccine potentially the first new shot against the global killer in a century.
A drug cocktail with Roche’s Tecentriq added two months to small-cell lung cancer patients’ lives, according to a study, aiding the Swiss group’s bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.